• Recruiting

NCT03031730: Phase 1: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy RRMM Myeloma


NCT03031730: Phase 1: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma


krt-232 amg232


Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma


This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving MDM2 Inhibitor KRT-232, lenalidomide, carfilzomib, and dexamethasone together may work better in treating patients with multiple myeloma.


Sponsor:

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT03031730


Official Title: A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

First Posted: January 26, 2017


Click here for details on ClinicalTrials.gov

 

Drug: Carfilzomib

Drug: Dexamethasone

Drug: Dexamethasone Sodium Phosphate

Drug: Lenalidomide

Drug: Navtemadlin

 

AMG 232


Navtemadlin (Code C116624)

AMG 232

AMG-232

KRT 232

KRT-232

KRT232

MDM2 Inhibitor KRT-232

Navtemadlin

NAVTEMADLIN

 

Locations:

United States, California

United States, Colorado

United States, Texas

United States, Utah

 


Posts Archive